2514 related articles for article (PubMed ID: 19433655)
41. The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease.
Molho ES; Factor SA; Weiner WJ; Sanchez-Ramos JR; Singer C; Shulman L; Brown D; Sheldon C
J Neural Transm Suppl; 1995; 45():225-30. PubMed ID: 8748629
[TBL] [Abstract][Full Text] [Related]
42. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients.
Manson AJ; Turner K; Lees AJ
Mov Disord; 2002 Nov; 17(6):1235-41. PubMed ID: 12465062
[TBL] [Abstract][Full Text] [Related]
43. Clinical features of 35 patients with Parkinson's disease displaying REM behavior disorder.
Ozekmekçi S; Apaydin H; Kiliç E
Clin Neurol Neurosurg; 2005 Jun; 107(4):306-9. PubMed ID: 15885389
[TBL] [Abstract][Full Text] [Related]
44. Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations.
Marras C; Lang A; Krahn M; Tomlinson G; Naglie G;
Mov Disord; 2004 Jan; 19(1):22-8. PubMed ID: 14743356
[TBL] [Abstract][Full Text] [Related]
45. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
Storch A; Trenkwalder C; Oehlwein C; Winkelmann J; Polzer U; Hundemer HP; Schwarz J
Parkinsonism Relat Disord; 2005 Sep; 11(6):393-8. PubMed ID: 15993640
[TBL] [Abstract][Full Text] [Related]
46. Efficacy and safety of piribedil in early combination with L-dopa in the treatment of Parkinson's disease: a 6-month open study.
Suwantamee J; Nidhinandana S; Srisuwananukorn S; Laptikultham S; Pisarnpong A; Chankrachang S; Bundhukul A
J Med Assoc Thai; 2004 Nov; 87(11):1293-300. PubMed ID: 15825702
[TBL] [Abstract][Full Text] [Related]
47. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.
Nyholm D; Nilsson Remahl AI; Dizdar N; Constantinescu R; Holmberg B; Jansson R; Aquilonius SM; Askmark H
Neurology; 2005 Jan; 64(2):216-23. PubMed ID: 15668416
[TBL] [Abstract][Full Text] [Related]
48. [Clozapine in the treatment of adverse psychiatric manifestations of long-term therapy with levodopa].
Svetel MV; Sternić NM; Filipović SR; Vojvodić NM; Kostić VS
Srp Arh Celok Lek; 1997; 125(7-8):203-6. PubMed ID: 9304232
[TBL] [Abstract][Full Text] [Related]
49. Patient-perceived involvement and satisfaction in Parkinson's disease: effect on therapy decisions and quality of life.
Grosset KA; Grosset DG
Mov Disord; 2005 May; 20(5):616-9. PubMed ID: 15719417
[TBL] [Abstract][Full Text] [Related]
50. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease.
Hauser RA; Lew MF; Hurtig HI; Ondo WG; Wojcieszek J; Fitzer-Attas CJ;
Mov Disord; 2009 Mar; 24(4):564-73. PubMed ID: 19086083
[TBL] [Abstract][Full Text] [Related]
51. Neurosurgery at an earlier stage of Parkinson disease: a randomized, controlled trial.
Schüpbach WM; Maltête D; Houeto JL; du Montcel ST; Mallet L; Welter ML; Gargiulo M; Béhar C; Bonnet AM; Czernecki V; Pidoux B; Navarro S; Dormont D; Cornu P; Agid Y
Neurology; 2007 Jan; 68(4):267-71. PubMed ID: 17151341
[TBL] [Abstract][Full Text] [Related]
52. Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study.
Ziegler M; Castro-Caldas A; Del Signore S; Rascol O
Mov Disord; 2003 Apr; 18(4):418-25. PubMed ID: 12671949
[TBL] [Abstract][Full Text] [Related]
53. Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease.
Weintraub D; Moberg PJ; Duda JE; Katz IR; Stern MB
J Am Geriatr Soc; 2004 May; 52(5):784-8. PubMed ID: 15086662
[TBL] [Abstract][Full Text] [Related]
54. Fluctuating functions related to quality of life in advanced Parkinson disease: effects of duodenal levodopa infusion.
Isacson D; Bingefors K; Kristiansen IS; Nyholm D
Acta Neurol Scand; 2008 Dec; 118(6):379-86. PubMed ID: 18547273
[TBL] [Abstract][Full Text] [Related]
55. Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations.
Reichmann H; Boas J; Macmahon D; Myllyla V; Hakala A; Reinikainen K;
Acta Neurol Scand; 2005 Jan; 111(1):21-8. PubMed ID: 15595934
[TBL] [Abstract][Full Text] [Related]
56. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
[TBL] [Abstract][Full Text] [Related]
57. Early addition of selegiline to L-Dopa treatment is beneficial for patients with Parkinson disease.
Mizuno Y; Kondo T; Kuno S; Nomoto M; Yanagisawa N
Clin Neuropharmacol; 2010; 33(1):1-4. PubMed ID: 19935410
[TBL] [Abstract][Full Text] [Related]
58. Efficacy, safety, and tolerability of overnight switching from immediate- to once daily extended-release pramipexole in early Parkinson's disease.
Rascol O; Barone P; Hauser RA; Mizuno Y; Poewe W; Schapira AH; Salin L; Sohr M; Debieuvre C;
Mov Disord; 2010 Oct; 25(14):2326-32. PubMed ID: 20669265
[TBL] [Abstract][Full Text] [Related]
59. Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects.
Lyons KE; Friedman JH; Hermanowicz N; Isaacson SH; Hauser RA; Hersh BP; Silver DE; Tetrud JW; Elmer LW; Parashos SA; Struck LK; Lew MF; Pahwa R
Clin Neuropharmacol; 2010; 33(1):5-10. PubMed ID: 19855267
[TBL] [Abstract][Full Text] [Related]
60. Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease.
Watts RL; Lyons KE; Pahwa R; Sethi K; Stern M; Hauser RA; Olanow W; Gray AM; Adams B; Earl NL;
Mov Disord; 2010 May; 25(7):858-66. PubMed ID: 20461803
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
